Targeting CXCR4 potentiates anti-PD-1 efficacy modifying the tumor microenvironment and inhibiting neoplastic PD-1

[1]  Hiromasa Morikawa,et al.  PD-1+ regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer , 2019, Proceedings of the National Academy of Sciences.

[2]  B. Wegiel,et al.  Blockade of Lactate Dehydrogenase-A (LDH-A) Improves Efficacy of Anti-Programmed Cell Death-1 (PD-1) Therapy in Melanoma , 2019, Cancers.

[3]  A. Sluder,et al.  Dual blockade of CXCL12‐CXCR4 and PD‐1–PD‐L1 pathways prolongs survival of ovarian tumor–bearing mice by prevention of immunosuppression in the tumor microenvironment , 2019, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[4]  R. Jain,et al.  Blocking CXCR4 alleviates desmoplasia, increases T-lymphocyte infiltration, and improves immunotherapy in metastatic breast cancer , 2019, Proceedings of the National Academy of Sciences.

[5]  B. Greve,et al.  Tumor microenvironmental plasmacytoid dendritic cells contribute to breast cancer lymph node metastasis via CXCR4/SDF-1 axis , 2019, Breast Cancer Research and Treatment.

[6]  E. Matera,et al.  The Antitumor Activity of Combinations of Cytotoxic Chemotherapy and Immune Checkpoint Inhibitors Is Model-Dependent , 2018, Front. Immunol..

[7]  C. Ries,et al.  Chemotherapy Combines Effectively with Anti–PD-L1 Treatment and Can Augment Antitumor Responses , 2018, The Journal of Immunology.

[8]  G. Ayers,et al.  Loss of CXCR4 in Myeloid Cells Enhances Antitumor Immunity and Reduces Melanoma Growth through NK Cell and FASL Mechanisms , 2018, Cancer Immunology Research.

[9]  H. Yao,et al.  Cancer Cell-Intrinsic PD-1 and Implications in Combinatorial Immunotherapy , 2018, Front. Immunol..

[10]  T. Curiel,et al.  Cell-intrinsic PD-L1 and PD-1 signal effects in bladder cancer , 2018, The Journal of Immunology.

[11]  Jedd D. Wolchok,et al.  Cancer immunotherapy using checkpoint blockade , 2018, Science.

[12]  R. Kerbel,et al.  Impact of Chemical-Induced Mutational Load Increase on Immune Checkpoint Therapy in Poorly Responsive Murine Tumors , 2018, Molecular Cancer Therapeutics.

[13]  A. Benammar Elgaaied,et al.  Targeting Tumor Metabolism: A New Challenge to Improve Immunotherapy , 2018, Front. Immunol..

[14]  C. Rosales.  Neutrophil: A Cell with Many Roles in Inflammation or Several Cell Types? , 2018, Front. Physiol..

[15]  B. Zhang,et al.  Programmed cell death‐1 (PD‐1) checkpoint blockade in combination with a mammalian target of rapamycin inhibitor restrains hepatocellular carcinoma growth induced by hepatoma cell–intrinsic PD‐1 , 2017, Hepatology.

[16]  E. Novellino,et al.  Structure-Activity Relationships and Biological Characterization of a Novel, Potent, and Serum Stable C-X-C Chemokine Receptor Type 4 (CXCR4) Antagonist. , 2017, Journal of medicinal chemistry.

[17]  A. Vater,et al.  Increasing Tumor-Infiltrating T Cells through Inhibition of CXCL12 with NOX-A12 Synergizes with PD-1 Blockade , 2017, Cancer Immunology Research.

[18]  E. Novellino,et al.  Targeting CXCR4 reverts the suppressive activity of T-regulatory cells in renal cancer , 2017, Oncotarget.

[19]  M. Barone,et al.  A novel CXCR4-targeted near-infrared (NIR) fluorescent probe (Peptide R-NIR750) specifically detects CXCR4 expressing tumors , 2017, Scientific Reports.

[20]  Michael D. Robbins,et al.  PD-1 blockade enhances elotuzumab efficacy in mouse tumor models. , 2017, Blood advances.

[21]  Robert Damoiseaux,et al.  Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression , 2017, Cell reports.

[22]  K. Flaherty,et al.  Granzyme B PET Imaging as a Predictive Biomarker of Immunotherapy Response. , 2017, Cancer research.

[23]  J. Wargo,et al.  Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy , 2017, Cell.

[24]  Simon J. Dovedi,et al.  Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery , 2016, Cancer Immunology Research.

[25]  E. Novellino,et al.  Exploring the N-Terminal Region of C-X-C Motif Chemokine 12 (CXCL12): Identification of Plasma-Stable Cyclic Peptides As Novel, Potent C-X-C Chemokine Receptor Type 4 (CXCR4) Antagonists. , 2016, Journal of medicinal chemistry.

[26]  T. Graeber,et al.  Response to Programmed Cell Death-1 Blockade in a Murine Melanoma Syngeneic Model Requires Costimulation, CD4, and CD8 T Cells , 2016, Cancer Immunology Research.

[27]  R. Weichselbaum,et al.  Combination of radiotherapy and vaccination overcomes checkpoint blockade resistance , 2016, Oncotarget.

[28]  G. Salzano,et al.  CXCR4-antagonist Peptide R-liposomes for combined therapy against lung metastasis. , 2016, Nanoscale.

[29]  B. Pollo,et al.  Targeting CXCR4 by a selective peptide antagonist modulates tumor microenvironment and microglia reactivity in a human glioblastoma model , 2016, Journal of experimental & clinical cancer research : CR.

[30]  L. Zitvogel,et al.  A Threshold Level of Intratumor CD8+ T-cell PD1 Expression Dictates Therapeutic Response to Anti-PD1. , 2015, Cancer Research.

[31]  George F. Murphy,et al.  Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth , 2015, Cell.

[32]  S. Scala.  Molecular Pathways: Targeting the CXCR4–CXCL12 Axis—Untapped Potential in the Tumor Microenvironment , 2015, Clinical Cancer Research.

[33]  R. Jain,et al.  CXCR4 inhibition in tumor microenvironment facilitates anti‐programmed death receptor‐1 immunotherapy in sorafenib‐treated hepatocellular carcinoma in mice , 2015, Hepatology.

[34]  D. Fearon,et al.  T cell exclusion, immune privilege, and the tumor microenvironment , 2015, Science.

[35]  S. Choi,et al.  Downregulation of UHRF1 promotes EMT via inducing CXCR4 in human cancer cells. , 2015, International journal of oncology.

[36]  J. Malaterre,et al.  Therapeutic DNA vaccination against colorectal cancer by targeting the MYB oncoprotein , 2015, Clinical & translational immunology.

[37]  Zhirong Zhang,et al.  Enhanced antitumor and anti-metastasis efficiency via combined treatment with CXCR4 antagonist and liposomal doxorubicin. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[38]  B. Jessen,et al.  Combination of 4-1BB Agonist and PD-1 Antagonist Promotes Antitumor Effector/Memory CD8 T Cells in a Poorly Immunogenic Tumor Model , 2014, Cancer Immunology Research.

[39]  Derek S. Chan,et al.  Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti–PD-L1 immunotherapy in pancreatic cancer , 2013, Proceedings of the National Academy of Sciences.

[40]  Andrea Ciarmiello,et al.  Preclinical Development of a Novel Class of CXCR4 Antagonist Impairing Solid Tumors Growth and Metastases , 2013, PloS one.

[41]  P. Delvenne,et al.  Tumor microenvironment converts plasmacytoid dendritic cells into immunosuppressive/tolerogenic cells: insight into the molecular mechanisms , 2013, Journal of leukocyte biology.

[42]  G. Dranoff,et al.  CXCL12/CXCR4 blockade induces multimodal antitumor effects that prolong survival in an immunocompetent mouse model of ovarian cancer. , 2011, Cancer research.

[43]  Jianrong Wu,et al.  Statistical Inference for Tumor Growth Inhibition T/C Ratio , 2010, Journal of biopharmaceutical statistics.

[44]  S. Narumiya,et al.  Tumorigenesis and Neoplastic Progression COX-2 and Prostaglandin EP 3 / EP 4 Signaling Regulate the Tumor Stromal Proangiogenic Microenvironment via CXCL 12-CXCR 4 Chemokine Systems , 2010 .

[45]  J. Allison,et al.  PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors , 2010, Proceedings of the National Academy of Sciences.

[46]  Srinivas Nagaraj,et al.  Myeloid-derived suppressor cells as regulators of the immune system , 2009, Nature Reviews Immunology.

[47]  S. Quezada,et al.  CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. , 2006, The Journal of clinical investigation.

[48]  G. Botti,et al.  Human Melanoma Metastases Express Functional CXCR4 , 2006, Clinical Cancer Research.

[49]  L. Cerchia,et al.  A novel antagonist of CXCR4 prevents bone marrow-derived mesenchymal stem cell-mediated osteosarcoma and hepatocellular carcinoma cell migration and invasion. , 2016, Cancer letters.